Catalog11 refs
Pancragen
BioregulatorsDigestiveMetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Trp / KEDW) from the Khavinson group, designed to target pancreatic tissue. Proposed to reach the cell nucleus, bind DNA, and tune activity of genes that build and maintain pancreatic cells, including master pancreatic genes such as PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6-1, and PAX4. Studied for supporting blood-sugar control and the insulin-producing endocrine pancreas, especially in aging. Approved in Russia for clinical use in pancreatic support; no FDA approval and no published human clinical trials.
Primary Uses
Pancreatic support
Glucose homeostasis
Digestive enzyme regulation
Age-related pancreatic function
Correction of metabolic disorders in elderly people
Correction of impaired glucose tolerance
Type 2 diabetes mellitus support
Corrects impaired glucose tolerance
Normalizes insulin levels
Normalizes C-peptide levels
Improves endocrine pancreatic function
Supports pancreatic cell differentiation
Regulates melatonin expression
Reduces metabolic syndrome incidence
Upregulates key pancreatic transcription factors
Blood sugar regulation
Age-related pancreatic decline
Pancreatic research
Support pancreatic function
May influence insulin and glucagon production
Blood sugar control
Chronic pancreatitis
Adjunct for type 2 diabetes
Glucose metabolism support
Insulin-producing beta cell support
Protocol Reference
Dose
100–200 mcg
Frequency
1-2 times daily
Half-life
Variable (complex)
Route
Oral
Evidence
Preclinical / Moderate Research (disputed)
Research References· 13
Research Models
BovineHumanRatrhesus monkeyrhesus monkeys
Also in Bioregulators